Key statistics
On Friday, Biogen Inc (IDP:STU) closed at 177.30, 1.58% above its 52-week low of 174.55, set on Sep 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 179.60 |
---|---|
High | 179.60 |
Low | 177.30 |
Bid | 178.40 |
Offer | 178.75 |
Previous close | 180.20 |
Average volume | 26.80 |
---|---|
Shares outstanding | 145.66m |
Free float | 145.42m |
P/E (TTM) | 25.12 |
Market cap | 29.04bn USD |
EPS (TTM) | 7.94 USD |
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
- Biogen Board Appoints Two New Independent Directors
- Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024
- Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
- Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
- Biogen Completes Acquisition of Human Immunology Biosciences
- “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
- TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
- FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
- Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel
More ▼